ReviewFunction (Oxford, England)2026
Melatonin receptor signaling in human pathologies: from molecular mechanisms to therapeutic targets.
Review in Function (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The therapeutic potential of melatonin: Focus on the SIRT1 signaling pathway.Molecular biology reports · 2026Review
- Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The melatonin receptor 1 A (MTNR1A), a highly conserved G protein-coupled receptor (GPCR), mediates crucial physiological functions. Its structure features an N-terminus responsible for melatonin binding and a C-terminus that initiates downstream signaling pathways to modulate target gene expression. Given MTNR1A's ability to form homodimers or heterodimers with other GPCRs, its expression levels are critical for the precise control of cellular signaling. This review article provides a comprehensive update on MTNR1A, highlighting recent developments concerning its expression distribution, gene regulation, protein motifs, and mediated signaling pathways. We also discuss the clinical relevance of single-nucleotide polymorphisms (SNPs) associated with the MTNR1A receptor and the range of diseases linked to its dysfunction. Current understanding and future perspectives regarding gene regulation and the stimulation of MTNR1A expression are critically addressed. Furthermore, we investigate the role of MTNR1A genetic variants in idiopathic osteoporosis and the association between decreased MTNR1A expression and membranous nephropathy. The systemic involvement of MTNR1A downregulation in cancer, fetal growth restriction, type 2 diabetes, and Parkinson's and Alzheimer's diseases is further underlined by its established biological functions. In conclusion, targeting MTNR1A-related downregulation and developing specific agonists or modulators offer a promising avenue for advancement in therapeutic medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.